{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023588","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.144830+00:00","generated_at":"2026-05-17T13:49:58.394999+00:00","sec_items":["2.05","5.02","5.03","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated","bullets":["Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.","Annual operating expenses to be reduced by ~$8 million when fully implemented; one-time charges not yet estimable.","CEO Barrett Evans and COO Colin Stott terminated effective immediately; both remain on the Board.","All preclinical programs (PHYX-001 through PHYX-005) paused; company pursuing partnerships or out-licensing.","Fiscal year-end changed from Dec 31 to Mar 31; transition report on Form 10-QT for Apr 1–Jun 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023588","json":"https://secwatch.observer/filing/0001641172-25-023588.json","markdown":"https://secwatch.observer/filing/0001641172-25-023588.md","text":"https://secwatch.observer/filing/0001641172-25-023588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/0001641172-25-023588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:49:58.394999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94d5bec543d7efdb6ccb7e744e3f974f58a6fe0a","claim":"Protagenic Therapeutics, Inc.new: Fiscal year-end changed from December 31 to March 31.","evidence_excerpt":"the Board approved a change in the Company’s fiscal year-end from December 31 to March 31, effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225023588/0001641172-25-023588-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"fiscal year change"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}